BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...senior director, center for external innovation, rare disease at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Healx Ltd....
...BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst BioMedica Kronos Bio Inc. Canbridge Pharmaceuticals Inc. Healx Ltd. Summit...
BioCentury | Oct 16, 2019
Company News

AI play Healx raises $56M to repurpose drugs for rare disease

...to treat them. The series B, announced Wednesday and led by Atomico, will help fund Healx Ltd.’s...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

...was VP and head of clinical development, regulatory and safety at Arcus Biosciences Inc. (NYSE:RCUS). Healx Ltd....
...Eaton and Hongjiang Li, Staff Writers Alnylam Pharmaceuticals Inc. Atreca Inc. AZTherapies Inc. Eli Lilly and Co. Gilead Sciences Inc. GlaxoSmithKline plc Healx Ltd. Hisamitsu...
Items per page:
1 - 3 of 3
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...senior director, center for external innovation, rare disease at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK). Healx Ltd....
...BioCentury Staff Nurix Therapeutics Inc. Xilio Therapeutics Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst BioMedica Kronos Bio Inc. Canbridge Pharmaceuticals Inc. Healx Ltd. Summit...
BioCentury | Oct 16, 2019
Company News

AI play Healx raises $56M to repurpose drugs for rare disease

...to treat them. The series B, announced Wednesday and led by Atomico, will help fund Healx Ltd.’s...
BioCentury | Jul 11, 2019
Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

...was VP and head of clinical development, regulatory and safety at Arcus Biosciences Inc. (NYSE:RCUS). Healx Ltd....
...Eaton and Hongjiang Li, Staff Writers Alnylam Pharmaceuticals Inc. Atreca Inc. AZTherapies Inc. Eli Lilly and Co. Gilead Sciences Inc. GlaxoSmithKline plc Healx Ltd. Hisamitsu...
Items per page:
1 - 3 of 3